Disease modification in axial spondyloarthritis

SARI İ., Haroon N.

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, vol.32, no.3, pp.427-439, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 3
  • Publication Date: 2018
  • Doi Number: 10.1016/j.berh.2019.02.007
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.427-439
  • Keywords: Spondylarthropathies, Ankylosing spondylitis, Disease progression, Outcomes assessment, Tumor necrosis factor-alpha, Non-steroidal anti-inflammatory agents, Smoking, Diagnostic imaging, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, SPINAL RADIOGRAPHIC PROGRESSION, BONE MORPHOGENETIC PROTEINS, TUMOR-NECROSIS-FACTOR, ANKYLOSING-SPONDYLITIS, STRUCTURAL DAMAGE, INFLAMMATION, EFFICACY, SECUKINUMAB, ENTHESITIS
  • Dokuz Eylül University Affiliated: Yes


The concept of "disease modification" refers to an intervention that modifies the natural clinical course of the disease along with improvement of symptoms. With regard to this, providing treatment that improves clinical signs and symptoms of axial spondyloarthritis (axSpA) and that impacts disease pathogenesis by slowing/halting bone formation is the main goal of this concept. It has been proven that currently available treatments including biologics and nonsteroidal anti-inflammatory drugs have a symptom-modifying effect in axSpA. The body of evidence showing a beneficial effect of biologic therapy on spinal damage is growing. In this article, by centralizing new bone formation as a main target of disease modification, we reviewed molecular mechanisms related to new bone formation, relevance of imaging studies on assessment of disease progression, clinical predictors of new bone formation, and disease-modifying properties of currently available treatments in axSpA. (C) 2019 Elsevier Ltd. All rights reserved.